Prostate-specific antigen

Semin Surg Oncol. Jan-Feb 2000;18(1):3-9. doi: 10.1002/(sici)1098-2388(200001/02)18:1<3::aid-ssu2>3.0.co;2-i.

Abstract

Prostate-specific antigen (PSA) has revolutionized the diagnosis and management of men with prostate cancer. Significant advances have been made since the early development of immunoassays. While PSA is useful for staging and monitoring of established disease, it has shown the greatest utility in the realm of early detection realm. PSA is the most important tumor marker; its importance in evaluating men for the possibility of prostate cancer is irrefutable. Enhancing specificity is a pressing need. In this regard, the recognition of the molecular forms of free PSA and complex PSA have shown the most promise and undoubtedly will result in fewer false-positive PSA test results. The salient literature is reviewed and commentary made on the current status of PSA with particular emphasis on methods to enhance its specificity in early detection and applications.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Adult
  • Aged
  • Biomarkers, Tumor / analysis*
  • Decision Making
  • False Positive Reactions
  • Humans
  • Male
  • Middle Aged
  • Neoplasm Staging / methods
  • Prostate-Specific Antigen / analysis*
  • Prostatic Neoplasms / pathology*

Substances

  • Biomarkers, Tumor
  • Prostate-Specific Antigen